Tumor-Induced Osteomalacia: Treatment Progress Using Burosumab, an Anti-FGF23 Monoclonal Antibody

J Bone Miner Res. 2021 Apr;36(4):625-626. doi: 10.1002/jbmr.4280. Epub 2021 Mar 19.

Author

Michael P Whyte^{1

2}

Affiliations

¹ Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.
² Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children-St. Louis, St. Louis, MO, USA.

PMID: 33740291
DOI: 10.1002/jbmr.4280

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Fibroblast Growth Factor-23
Fibroblast Growth Factors
Humans
Neoplasms, Connective Tissue*
Osteomalacia
Paraneoplastic Syndromes

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
FGF23 protein, human
Fibroblast Growth Factors
Fibroblast Growth Factor-23
burosumab

Supplementary concepts

Oncogenic osteomalacia